Project Grant R50CA305001
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$126K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
This federal Project Grant award, totaling $635,033, was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The Johns Hopkins University. The award will fund research to advance understanding of the genetic basis of a recently recognized cancer-prone syndrome caused by long telomere length. The key objectives are to identify additional novel genetic mechanisms for this "long telomere syndrome," define their role in familial cancer...
The federal Project Grant award F31CA295091 is funded by the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program. The $119,922 award supports research to investigate the role of the Fanconi Anemia (FA) pathway in driving a chromosomal abnormality called chromothripsis, which is frequently observed in cancer genomes. The research aims to comprehensively identify regions of micronucleated chromosomes undergoing FA pathway processing during mitosis, and to...
This Project Grant award of $160,330, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program, supports research to investigate the biochemical determinants of genome instability induced by eukaryotic topoisomerase II. The research aims to understand how the biochemical properties of topoisomerases, along with other factors like chromatin structure and DNA repair pathways, contribute to genome instability. Key project...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $541,682 to The Trustees of Columbia University in the City of New York for a 5-year period from July 3, 2024 to June 30, 2029. The project aims to better understand the mechanisms responsible for the assembly of DNA repair domains in cancer cells and evaluate the consequences of these domains following treatment with chemotherapeutic drugs....
This Project Grant award of $432,614.00 from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research at Duke University to investigate the relationship between chromosomal instability, 17p loss, and NDE1 dependence in cancer cells. The goal is to define the genetic dependencies resulting from these factors and assess the therapeutic potential of targeting NDE1 in cancers with increased chromosomal instability and 17p loss. The award period...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $159,500.00 to the University of California, San Diego to investigate the molecular mechanisms underlying the initiation of heterochromatin, a tightly packed form of DNA essential for genome stability and tumor suppression. The key focus is on understanding the interplay between heterochromatin protein 1 (HP1) and the signal transducer and activator of transcription...
This $1,449,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to study the fundamental regulation of extrachromosomal DNA (ecDNA) in cancer genomes. The project aims to develop new live-cell chromatin labeling strategies and integrate advanced imaging, synthetic genome engineering, and optical/genetic perturbation to systematically investigate how ecDNA orchestrates massive...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...